Herein, identification of the predictive role of PIK3CA mutation status on the clinical outcomes of PI3K inhibitors should be of great priority to benefit the diagnosis and prognosis for patients with HR+ breast cancer. The gene discussed is PIK3CA; the disease is breast cancer.